Huang R, Shi XL, Wang YF, Yang F, Wang TT, Peng CX. Apatinib for treatment of a pseudomyxoma peritonei patient after surgical treatment and hyperthermic intraperitoneal chemotherapy: A case report. World J Clin Cases 2019; 7(22): 3881-3886 [PMID: 31799318 DOI: 10.12998/wjcc.v7.i22.3881]
Corresponding Author of This Article
Cun-Xu Peng, Doctor, Professor, Surgeon, Department of Gynecology, The Affiliated Hospital of Jining Medical University, Jining Medical University, 89 Guhuai Road, Jining 272000, Shandong Province, China. pengcunxu@aliyun.com
Research Domain of This Article
Obstetrics & Gynecology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Rong Huang, Fei Yang, Department of Clinical Medicine, Jining Medical University, Jining 272000, Shandong Province, China
Xiu-Ling Shi, Yun-Fei Wang, Ting-Tao Wang, Cun-Xu Peng, Department of Gynecology, The Affiliated Hospital of Jining Medical University, Jining Medical University, Jining 272000, Shandong Province, China
Author contributions: Huang R drafted, reviewed, and revised the manuscript; Peng CX and Wang TT were the primary physicians during the patient’s inpatient stay; Shi XL provided the images; Wang YF and Yang F were involved in the editing and overseeing of the text; all authors have read and approved the final manuscript.
Informed consent statement: Informed consent as documented by signature was obtained from the patient.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Cun-Xu Peng, Doctor, Professor, Surgeon, Department of Gynecology, The Affiliated Hospital of Jining Medical University, Jining Medical University, 89 Guhuai Road, Jining 272000, Shandong Province, China. pengcunxu@aliyun.com
Telephone: +86-17562232048
Received: July 20, 2019 Peer-review started: July 23, 2019 First decision: September 9, 2019 Revised: September 17, 2019 Accepted: October 5, 2019 Article in press: October 5, 2019 Published online: November 26, 2019 Processing time: 128 Days and 17.7 Hours
Abstract
BACKGROUND
Pseudomyxoma peritonei (PMP) is a rare benign, but progressive, disease according to myxoma histopathology. Surgical resection is the preferred and most effective treatment, but the outcomes are often unsatisfactory.
CASE SUMMARY
A 63-year-old Chinese woman with PMP received apatinib at a daily dose of 0.5 mg for 15 d per cycle and at a daily dose of 0.4 mg to date for recurrent abdominal distension after surgical treatment and hyperthermic intraperitoneal chemotherapy. During the follow-up period, apatinib was the maintenance treatment with a progression-free period of 10 mo and the toxicity of apatinib was controllable and tolerable. Unfortunately, recurrence occurred 10 mo after administration. After two operations, the patient gave up treatment at the 18th mo and eventually died of intestinal obstruction and multiple organ failure.
CONCLUSION
Apatinib may be an option for recurrent PMP after surgical treatment, but this conclusion remains to be confirmed.
Core tip: The preferred treatment for pseudomyxoma peritonei (PMP) is surgery, but it is easy to relapse after surgery. There is currently no good treatment for patients with postoperative recurrence. In this work, a PMP patient received apatinib for recurrent abdominal distension after surgical treatment and hyperthermic intraperitoneal chemotherapy. After treatment with apatinib, the recurrence time was significantly prolonged. Apatinib, a small-molecule oral inhibitor with anti-angiogenic function, may be an option for recurrent PMP after surgical treatment.
